21/04/2017 18:39:45

MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants

Hoersholm; April 21st 2017 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants the share capital has been increased by nominal DKK 6,190 and the number of shares has been increased with 123,800.

The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0.05.

Proceeds to the company are DKK 64,376.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,174,452 and will after the capital increase be DKK 1,180,642. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.

The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI

Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:

CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication

E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com

Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 21

st

2017.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Increases its share capital due to warrant exercise April 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medical Prognosis Institute via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker mine analyse af Pandoras forretnings..
80
10 Feb
I:SP500
Hejsa alle sammen   Så er det vinterferie og hvad kan tiden bruges til, ja lidt teknisk på stockmark..
36
13 Feb
 
Lad dog Henrik dø i fred i stedet for at komme med jeres dumsmarte bemærkninger   Det er upazsende u..
28
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
26
11 Feb
I:SP500
Prisdannelsen over S&P 500 med anvendelsen af candelstik med en månedlig tidsramme:   https://invst...
24
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
19
15 Feb
OMXC20
Kære alle. Jeg har flere gange tilbudt at svare på investeringsspørgsmål for at bidrage til at så ma..
19
13 Feb
 
nu syntes jeg i er for åndsvage manden er ved at dø forhelvede
18
10 Feb
PNDORA
Jeg forstår ikke, hvordan man kan være så blæst i hovedet, som du er.
18
12 Feb
FING-B
Fjols
17

Elliott Capital Advisors, L.P : Form 8.3 - MELROSE INDUSTRIES PLC

16/02/2018 15:25:32
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners an..

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers

16/02/2018 13:00:19
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management   SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of cu..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM plc

16/02/2018 10:19:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PHOTO RELEASE--Huntington Ingalls Industries Awarded $1.43 Billion Contract For The Construction of LPD 29
2
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
3
QUANTUM CORPORATION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM
4
WELLS FARGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Wells Fargo & Company - WFC
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 February 2018 19:09:54
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180209.1 - EUROWEB4 - 2018-02-17 20:09:54 - 2018-02-17 19:09:54 - 1000 - Website: OKAY